Reproductive & sexual-function research
PT-141 (Bremelanotide): Research, Mechanism & Current Evidence
Melanocortin receptor agonist approved for low sexual desire in premenopausal women; acts on the brain, not blood flow.
Also known as bremelanotide · Vyleesi · PT141 · melanocortin receptor agonist · Bremelanotide
What is PT-141?
PT-141, known generically as bremelanotide and marketed as Vyleesi, is a synthetic peptide that acts on melanocortin receptors in the brain. It originated as a by-product of research into melanotan compounds developed for pigmentation.
The FDA approved it in 2019 for hypoactive sexual desire disorder in premenopausal women — a specific and narrow indication.
Status: Approved by the FDA (2019) for HSDD in premenopausal women.
What is PT-141 researched for?
The registration programme studied sexual desire and associated distress in premenopausal women.
Earlier research examined erectile response in men, including in cases that had not responded to PDE5 inhibitors, though this did not lead to approval in men.
- FDA-approved for treatment of HSDD in premenopausal women.
- Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.
- Enhances sexual arousal and desire in women.
- Reduces distress related to low sexual desire.
- Enhanced satisfaction reported in clinical trials.
How does PT-141 work?
Most well-known treatments for erectile difficulty work on blood vessels, relaxing them so blood flow increases. PT-141 works differently: it acts centrally, in the nervous system, on melanocortin receptors — chiefly MC3R and MC4R — that are involved in the pathways governing arousal and desire.
That distinction is why it is studied in desire disorders rather than purely mechanical ones.
Reported targets: MC3R, MC4R, melanocortin receptor
What does the research show?
Two randomised, placebo-controlled phase 3 trials, RECONNECT, supported approval. The improvements over placebo were statistically significant but modest in absolute terms, which is characteristic of trials in this area.
Nausea was the most common adverse effect, reported by a substantial minority of participants. Transient increases in blood pressure and reductions in heart rate were also documented.
Limitations of the current evidence
The approved indication is narrow: premenopausal women with acquired, generalised hypoactive sexual desire disorder. Evidence outside that group is limited.
Effect sizes in the registration trials were small relative to placebo, and the trials measured self-reported outcomes.
References
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics and gynecology · 2019
Two identical phase 3, randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960). Bremelanotide 1.75mg SubQ significantly improved sexual desire and reduced related distress in premenopausal women with HSDD.
Controlled clinical trial · PMID 31599840
Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile Dysfunction Diamond LE, Earle DC, Rosen RC, et al. Urology
2004
Intranasal PT-141 produced dose-dependent increase in erectile activity at doses >7mg, with onset in ~30 minutes. Safe and well-tolerated in both healthy men and ED patients.
Controlled clinical trial
The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal Women Clayton AH, Kingsberg SA, Goldstein I, et al. CNS Spectrums
2021
Bremelanotide activates MC4R in the medial preoptic area of the hypothalamus, increasing dopamine release. CNS mechanism of action independent of peripheral vascular effects.
Safarinejad MR, Hosseini SY · The Journal of urology · 2008
342 men with ED unresponsive to sildenafil randomized to 10mg bremelanotide intranasal spray vs placebo. Demonstrated effectiveness in PDE5 inhibitor-resistant cases.
Controlled clinical trial · PMID 18206919
Diamond LE, Earle DC, Rosen RC, et al. · International journal of impotence research · 2004
Controlled clinical trial · PMID 14963471
Pfaus JG, Sadiq A, Spana C, et al. · CNS spectrums · 2022
PMID 33455598
Common questions
How is PT-141 different from Viagra if both treat erectile dysfunction?
Completely different mechanisms. Viagra (sildenafil) works peripherally by dilating blood vessels in the penis (PDE5 inhibition). PT-141 works centrally in the brain via melanocortin receptors to trigger sexual desire and arousal independent of blood flow. PT-141 can even work in PDE5 inhibitor-resistant cases because it bypasses the vascular system entirely.
Why does PT-141 cause nausea in 40% of people?
PT-141 activates melanocortin receptors broadly in the brain, not just sexual arousal centers. Off-target activation in nausea-control areas is a known side effect. Taking an anti-nausea medication 30 minutes before PT-141 (as recommended in the file) significantly reduces this. Many users find pre-medication worthwhile for the benefit.